High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia
Status:
Unknown status
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare efficacy and safety of add-on treatment with a
moderately high dose of D-serine, an NMDA-glycine site agonist, in young, recent onset
schizophrenia patients who suffer from significant symptoms despite treatment with
antipsychotics.